We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
- Authors
Park, So Young; Jun, Ji Eun; Jeong, In-Kyung; Ahn, Kyu Jeung; Chung, Ho Yeon; Hwang, You-Cheol
- Abstract
Context Low-density lipoprotein cholesterol (LDL-C)-lowering therapy is considerably important in preventing cardiovascular disease (CVD) among patients with diabetes. Studies comparing CVD, stroke, and mortality outcomes of low- or moderate-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy in patients with diabetes remain lacking. Objective This study compared the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low- or moderate-intensity statins and ezetimibe and high-intensity statin monotherapy in patients with diabetes using the Korean National Health Insurance claims database. Methods Patients aged ≥20 years with type 2 diabetes and dyslipidemia were enrolled. The combination therapy of low- or moderate-intensity statin and ezetimibe was compared with high-intensity statin monotherapy after a propensity score–matched analysis. The incidence of composite outcomes consisting of MI, stroke, and all-cause death and each component were analyzed. Results In moderate-intensity statin therapy with ezetimibe combination therapy, LDL-C (74 ± 37.9 mg/dL vs 80.8 ± 38.8 mg/dL, P <.001) and the incidence of composite outcomes were lower (hazard ratio 0.85, 95% CI 0.74-0.98) than those in high-intensity statin monotherapy. Meanwhile, no significant difference was observed in the LDL-C levels and composite outcomes between low-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy. Conclusion Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C–lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.
- Subjects
TYPE 2 diabetes; DRUG-eluting stents; STATINS (Cardiovascular agents); EZETIMIBE; LDL cholesterol; NATIONAL health insurance
- Publication
Journal of Clinical Endocrinology & Metabolism, 2024, Vol 109, Issue 7, p1883
- ISSN
0021-972X
- Publication type
Article
- DOI
10.1210/clinem/dgad714